Studies have shown that active fund managers routinely underperform the S&P500 index*​

Axsome Therapeutics, Inc. (NASDAQ: AXSM)

AXSM Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
51%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
4%

AXSM Stock Analysis

AXSM PE Ratio:

AXSM PEG Ratio: Not Available

AXSM Forward EPS Growth (12 month): 0.00%

AXSM PS Ratio: 17

AXSM PSG Ratio: 0.3

AXSM Forward Revenue Growth (12 month): 65.10%

AXSM Articles

No data was found